SOURCE: TheSUBWAY.com

September 15, 2006 09:14 ET

TheSUBWAY.com Posts Stock Pick List: Product Targeted for Phase 2B Clinical Trials!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

WESTON, FL -- (MARKET WIRE) -- September 15, 2006 -- TheSUBWAY.com names the following stocks to its Stock Pick List: CepTor Corporation (OTCBB: CEPO), Acergy S.A. (NASDAQ: ACGY), SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), ASML Holding N.V. (NASDAQ: ASML).

CepTor Corporation (OTCBB: CEPO), a biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced today that it has signed a Letter of Intent (LOI) with Ferring International Center, S.A. in which Ferring plans to divest and CepTor plans to purchase recombinant human copper zinc superoxide dismutase (r-h CuZnSOD or SOD).

Bill Pursley, Chairman and CEO of CepTor, remarked, "Considering our staff's experience in this area, SOD represents a perfect fit for the Company. SOD is an advanced stage product with orphan status in the U.S. and EU, representing a $400 million market opportunity for an unmet medical need. Ferring has been extremely supportive and its efficiency and expediency throughout this process is representative of the company's entrepreneurial spirit."

Other stocks highlighted include Acergy S.A. (NASDAQ: ACGY): Stock Pick List, down 5% on 1 million shares, SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN): Stock Pick List, down 1% on 1 million shares, ASML Holding N.V. (NASDAQ: ASML): Stock Pick List, down 1% on 2 million shares.

“Stocks have been hard-pressed to pick a direction in trading lately, going on a tear for a few days, only to see those gains wane in the next several sessions. The Dow Jones Industrial Average is, in fact, just now beginning to break out late in the year, just now breaking out and hovering nicely above the level it was at when the Federal Reserve began raising rates over a year ago.” More is available at: http://www.thesubway.com.

TheSUBWAY.com’s Daily Stock Updates:

TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a “long term” view of any of the companies listed. For more go to http://www.thesubway.com.

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated zero dollars for CEPO. CRG has not been compensated but could receive up to one hundred thousand dollars worth of cash or stock for CEPO. CRG intends to sell its shares. CRG has sold approximately zero CEPO shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Contact Information